Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence
- PMID: 17626202
- PMCID: PMC6672614
- DOI: 10.1523/JNEUROSCI.4540-06.2007
Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence
Abstract
Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly inherited neurodegenerative disorder caused by the expansion of a CAG repeat in the MJD1 gene resulting in an expanded polyglutamine repeat in the ataxin-3 protein. To study the course of the disease, we generated transgenic mice for SCA3 using full-length ataxin-3 constructs containing 15, 70, or 148 CAG repeats, respectively. Control mice (15 CAGs) were phenotypically normal and had no neuropathological findings. However, mice transgenic for ataxin-3 with expanded polyglutamine repeats were severely affected by a strong neurological phenotype with tremor, behavioral deficits, strongly reduced motor and exploratory activity, a hunchback, and premature death at 3 to 6 months of age. Neuropathological examination by immunohistochemical staining revealed ubiquitin- and ataxin-3-positive intranuclear inclusion bodies in a multitude of neurons. Directing ataxin-3 with 148 CAGs to the nucleus revealed an even more pronounced phenotype with more inclusions and earlier death, whereas mice transgenic with the same construct but attached to a nuclear export signal developed a milder phenotype with less inclusions. These studies indicate that nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3 in vivo.
Figures










Similar articles
-
A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.Neurobiol Dis. 2015 Jan;73:174-88. doi: 10.1016/j.nbd.2014.09.020. Epub 2014 Oct 7. Neurobiol Dis. 2015. PMID: 25301414
-
Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.Neurobiol Dis. 2010 Apr;38(1):116-24. doi: 10.1016/j.nbd.2010.01.005. Epub 2010 Jan 15. Neurobiol Dis. 2010. PMID: 20079840
-
Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.Brain Pathol. 2006 Jul;16(3):218-27. doi: 10.1111/j.1750-3639.2006.00022.x. Brain Pathol. 2006. PMID: 16911479 Free PMC article.
-
Progress in pathogenesis studies of spinocerebellar ataxia type 1.Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1079-81. doi: 10.1098/rstb.1999.0462. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434309 Free PMC article. Review.
-
Machado-Joseph disease/spinocerebellar ataxia type 3.Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9. Handb Clin Neurol. 2012. PMID: 21827905 Free PMC article. Review.
Cited by
-
Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.PLoS One. 2012;7(9):e43563. doi: 10.1371/journal.pone.0043563. Epub 2012 Sep 6. PLoS One. 2012. PMID: 22970133 Free PMC article.
-
Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.Cerebellum. 2013 Aug;12(4):441-55. doi: 10.1007/s12311-012-0432-0. Cerebellum. 2013. PMID: 23242710
-
Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2).Int J Clin Exp Pathol. 2009;2(1):34-47. Epub 2008 Apr 24. Int J Clin Exp Pathol. 2009. PMID: 18830387 Free PMC article.
-
From pathways to targets: understanding the mechanisms behind polyglutamine disease.Biomed Res Int. 2014;2014:701758. doi: 10.1155/2014/701758. Epub 2014 Sep 21. Biomed Res Int. 2014. PMID: 25309920 Free PMC article. Review.
-
Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.Mol Ther Nucleic Acids. 2017 Sep 15;8:232-242. doi: 10.1016/j.omtn.2017.06.019. Epub 2017 Jun 29. Mol Ther Nucleic Acids. 2017. PMID: 28918024 Free PMC article.
References
-
- Albrecht M, Golatta M, Wüllner U, Lengauer T. Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem. 2004;271:3155–3170. - PubMed
-
- Baybutt H, Manson J. Characterisation of two promoters for prion protein (PrP) gene expression in neuronal cells. Gene. 1997;184:125–131. - PubMed
-
- Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum Mol Genet. 2005;14:3065–3078. - PubMed
-
- Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet. 2005;14:565–574. - PubMed
-
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases